Drug Profile
Anti-LCG monoclonal antibody - eXegenics
Alternative Names: LCG monoclonal antibody - eXegenics; Lung cancer gene - monoclonal antibodyLatest Information Update: 25 Aug 2003
Price :
$50
*
At a glance
- Originator eXegenics
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lung cancer
Most Recent Events
- 25 Aug 2003 Discontinued - Phase-I for Lung cancer in USA (unspecified route)
- 01 Aug 2003 Suspended - Phase-I for Lung cancer in USA (unspecified route)
- 09 Nov 2001 Cytoclonal Pharmaceutics is now called eXegenics